Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
Intimation under Regulation 30 of SEBI Listing Regulations read with SEBI Circular dated July 13, 202311-01-2024
11-01-2024
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issuance of LOC - Krishna Kishore Busetty08-01-2024
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39 (3) of SEBI (LODR) Regulations - 2015 - Geeta K Doshi08-01-2024
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Acquisition
Intimation under Regulation 30 of SEBI Listing Regulations read with SEBI Circular dated July 13, 202305-01-2024
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Acquisition
Investment in AMP Energy02-01-2024
Strides Pharma Science Ltd - 532531 - Intimation Under Regulation 30 Of SEBI LODR
Update on Sale of Manufacturing Facility in Singapore29-12-2023
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issuance of LOC to Gunapal Kunder29-12-2023
The three companies eyeing Macquarie's Strides solar projects
Gentari, Actis and Sekura Energy Ltd, backed by Edelweiss Infrastructure Yield Plus Fund, have shown interest in Stride.28-12-2023
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 - Deepak Abichandani26-12-2023
Strides Pharma Science Ltd - 532531 - Update On Stelis Biopharma''s Transaction With Syngene For Sale Of Stelis'' Unit 3 Multi-Model Facility In Bengaluru
Update on Stelis Biopharma''s transaction with Syngene for sale off Stelis'' Unit 3 Multi-Model Facility in Bengaluru23-12-2023